The CAPItello-280 study (NCT05348577) was investigating Truqap in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in p ...

AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women ...

After several years of growing expectation, AstraZeneca’s long-awaited MYSTIC immune ... That doesn't mean it is all over for Imfinzi in lung cancer: the drug has hit its PFS target as a ...

A new commercial for AstraZeneca’s Truqap ... breast cancer who have experienced recurrence or progression on other treatments. The approval was based on study data showing that the drug combo ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate ... stage breast cancer. As for the study’s secondary ...

AstraZeneca ... drug cocktail when it was combined with another medicine, Pertuzumab. The trial was testing Enhertu’s effectiveness against HER2-positive metastatic breast cancer.

AstraZeneca (NASDAQ ... improvement as a first line treatment of metastatic breast cancer, compared to standard care. Enhertu, an antibody drug conjugate, is being jointly developed and ...

Also Read: European Drug Regulator Approves AstraZeneca’s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings The PFS improvement was seen across all pre-specified patient subgroups ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in a subset of ...

Daiichi Sankyo and ... to leverage Daiichi’s DXd ADC Technology and has secured approval in more than 75 nations for the treatment of HER2-positive breast cancer. Daiichi Sankyo research and ...

(RTTNews) - Daiichi Sankyo Co., Ltd. (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan), co-developed and commercialized with British drug major AstraZeneca Plc. (AZN.L, AZN), Plus ...